THNR provides access to global companies expected to economically benefit from weight loss drug development. THNR seeks investment results that generally correspond to the performance (before fees and expenses) of the VettaFi Weight Loss Drug & Treatment Index.
Amplify Weight Loss Drug & Treatment ETF · Issued by Amplify
| NVO | Novo Nordisk AS ADR | 8.89% |
| LLY | Eli Lilly and Co | 8.61% |
| 1801.HK | Innovent Biologics Inc | 6.33% |
| REGN | Regeneron Pharmaceuticals Inc | 6.02% |
| 1093.HK | CSPC Pharmaceutical Group Ltd | 5.75% |
| SRRK | Scholar Rock Holding Corp | 5.69% |
| AMGN | Amgen Inc | 5.59% |
| MRK | Merck & Co Inc | 5.48% |
| ABBV | AbbVie Inc | 5.11% |
| PFE | Pfizer Inc | 5.00% |
No recent news for THNR. The ingest cron pulls every 15 minutes during market hours.